<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-97185</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome</dc:title>
<dc:description xml:lang="en">The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010 (AU)</dc:description>
<dc:creator>Hernández Mijares, Antonio</dc:creator>
<dc:creator>Carey, Vincent J</dc:creator>
<dc:creator>Pintó Salas, Xavier</dc:creator>
<dc:creator>Botet Montoya, Juan Pedro</dc:creator>
<dc:creator>Hermans, Michel P</dc:creator>
<dc:creator>Sacks, Frank M</dc:creator>
<dc:creator>Fruchart, Jean-Charles</dc:creator>
<dc:creator>Millán Núñez-Cortés, Jesús</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La Fundación R3i (Residual Risk Reduction initiative), una organización académica, multinacional e independiente, está llevando a cabo el estudio REALIST (REsidual risk, LIpids and Standard Therapies) en más de 40 centros de diferentes países. Se trata de un estudio epidemiológico retrospectivo, que está diseñado para proporcionar nuevos datos referentes al riesgo residual de episodios coronarios mayores atribuible a las alteraciones lipídicas en pacientes que reciben los tratamientos de referencia actuales. Sus resultados iniciales se esperan para mediados del año 2010, y los resultados globales para finales del año 2010 (AU)</dc:description>
<dc:source>Endocrinol Nutr;58(1): 38-47, ene. 2011. tab</dc:source>
<dc:identifier>ibc-97185</dc:identifier>
<dc:title xml:lang="es">Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d963^s22073</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d7130^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d52613^s22080</dc:subject>
<dc:subject>^d7130^s22080</dc:subject>
<dc:subject>^d50504^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201101</dc:date>
</metadata>
</record>
</ibecs-document>
